Author

Tiziano Bernasocchi

Broad InstituteORCID 0000-0002-7130-5317Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

Andrea RinaldiiD· 1 shared Arianna VallergaiD· 1 shared Bryce OrdwayiD· 1 shared Chenxu GuoiD· 1 shared Daniela BossiiD· 1 shared Eric F. ZaniewskiiD· 1 shared Esther RheinbayiD· 1 shared Eva CoreyiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrea RinaldiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A SIRT5-induced metabolic switch underlies chemoresistance and ATR checkpoint dependence in triple-negative breast cancer

Zuen Ren, Tiziano Bernasocchi, Kiran Kurmi, Chenxu Guo, Kevin Jiang, Eric F. Zaniewski, Garrett Lam, Kazi Nazrul Islam, Shakchhi Joshi, Xin Li, Ilze Smidt, Robert Morris, Bryce Ordway, Veerle Bossuyt, Gary X. Wang, , Leif William Ellisen

This study identifies SIRT5-induced metabolic changes as a driver of chemoresistance in TNBC and reveals ATR checkpoint dependence as a therapeutic vulnerability.

bioRxiv · Apr 9, 2026 · PreprintCancer Biology

TRIM24 Degradation Counteracts Adaptation to Androgen Receptor Inhibition in Prostate Cancer

Daniela Bossi, Arianna Vallerga, Giuseppe Salfi, Nicolò Formaggio, Valentina Ceserani, Zhang Jichang, Tiziano Bernasocchi, Andrea Rinaldi, Lukas Bubendorf, Simone Mosole, Eva Corey, Marco Bolis, Matteo Pecoraro, Roger Geiger, Wouter R. Karthaus, , Jean-Philippe Paul. Theurillat

This study identifies TRIM24 as a target for preventing prostate cancer progression by degrading it to counteract AR inhibition adaptation and tumor relapse.

bioRxiv · Aug 21, 2025 · PreprintCancer Biology